Primary completion of ABTECT - Maintenance

What happened

Resolved by the sponsor's topline disclosure of the trial's primary endpoint: met with statistical significance is success; missed is failure; co-primary endpoints split, or significance reached only in a pre-specified subgroup, is mixed.phase3_topline.v1 v1, written when the event was created

What the research said before

event-not-joinedsealed 2026-09-22, before the readout

This is the snapshot as it stood before the event, sealed then rather than reconstructed now — which is the only version of a “before” worth printing.

What it says now

What changed

The research behind this event has not been regenerated since it resolved on 2026-09-22. Opening the company regenerates it, and this section fills on the next build.

Sources

• “On June 1, 2026 , we announced positive results from Part 1 of the Phase 3 ABTECT 44-week maintenance trial, demonstrating strong efficacy, including robust endoscopic remission, and on June 29, 2026, we announced positive topline results from Part 2 of the maintenance trial.”SEC EDGAR, read 22 Sep 2026
• “primaryCompletionDateStruct: {"date": "2026-04-28", "type": null}”ClinicalTrials.gov, read 21 Sep 2026